These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 24661849)
1. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849 [TBL] [Abstract][Full Text] [Related]
2. Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Kitano M; Millo C; Rahbari R; Herscovitch P; Gesuwan K; Webb RC; Venkatesan AM; Phan GQ; Hughes MS; Libutti SK; Nilubol N; Linehan WM; Kebebew E Surgery; 2011 Dec; 150(6):1122-8. PubMed ID: 22136831 [TBL] [Abstract][Full Text] [Related]
5. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206 [TBL] [Abstract][Full Text] [Related]
6. [18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome. Kok J; Lin M; Wong V; Campbell P; Lin P Clin Endocrinol (Oxf); 2009 Apr; 70(4):657-9. PubMed ID: 18811723 [No Abstract] [Full Text] [Related]
7. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature. Guan ZW; Xu BX; Wang RM; Sun L; Tian JH Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055 [TBL] [Abstract][Full Text] [Related]
9. Potential value of EUS in pancreatic surveillance of VHL patients. van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551 [TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT detects clinically occult pancreatic cancer in a case of Von Hippel-Lindau syndrome. Kulkarni M; Purandare N; Zade A; Agrawal A; Shah S; Rangarajan V Clin Nucl Med; 2013 Jul; 38(7):e302-3. PubMed ID: 23486326 [TBL] [Abstract][Full Text] [Related]
11. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985 [TBL] [Abstract][Full Text] [Related]
12. The utility of Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201 [TBL] [Abstract][Full Text] [Related]
13. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161 [TBL] [Abstract][Full Text] [Related]